George E. Woody
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
George E. Woody has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Anna Pecoraro
6 shared publications- Charles P. O'Brien
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6178, USA
4 shared publications - Evgeny Krupitsky
Saint Petersburg First Pavlov State Medical University, Saint Petersburg 197022, Russia; V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Saint Petersburg 192019, Russia
4 shared publications - A. Thomas McLellan
Treatment Research Institute, Philadelphia, PA 19106, USA
3 shared publications David Metzger
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
3 shared publicationsLester Luborsky
3 shared publications
Latest Publications
- Open Access
- 1 May 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 43, 1-6
Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan
- 1 May 2017
- Published by Elsevier in International Journal of Drug Policy
- Vol. 43, 1-6
Open AccessCauses of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan
- 7 April 2016
- Published by BMJ in Evidence Based Mental Health
- Vol. 19 (2) , e9
Clonidine: new use of an old medication to reduce stress-related substance use
- 7 April 2016
- Published by BMJ in Evidence Based Mental Health
- Vol. 19 (2) , e9
Clonidine: new use of an old medication to reduce stress-related substance use
- 27 February 2016
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 11 (3) , 401-407
Antagonist Models for Relapse Prevention and Reducing HIV Risk
Naltrexone is an antagonist that binds tightly to mu-opioid receptors and blocks the subjective and analgesic effects of opioids. It does not produce physiologic dependence and precipitates withdrawal if administered to an opioid dependent person, thus starting it must begin with detoxification. It was first available in the mid-1970s as a 50 mg tablet that blocked opioids for 24-36 h if taken daily, or every 2-3 days at higher doses - for example: 100 mg Monday and Wednesday, 150 mg on Friday. From a pharmacological perspective it worked very well and was hoped to be an effective treatment but results were disappointing due to low patient interest and high dropout followed by relapse. Interest in it waned but rose again in the late 1990's when injecting opioid use and the rapid spread of HIV in the Russian Federation converged with an international interest in reducing the spread of HIV. One result was a series of meetings sponsored by the U.S. National Institute on Drug Abuse (NIDA) and Pavlov State Medical University in St. Petersburg, Russian Federation, on ways to reduce the spread of HIV in that country. Addiction treatment was a clear priority and discussions showed that naltrexone could have a role since agonist treatment is against Russian law but naltrexone is approved and the government funds over 25,000 beds for detoxification, which is the first step in starting naltrexone treatment. These meetings were followed by NIDA studies that showed better compliance to oral naltrexone than in prior U.S. studies with the expected reductions in HIV injecting risk for those that stayed in treatment. These events and findings provided a background and identified an infrastructure for the study that led to FDA approval of extended release injectable naltrexone for preventing relapse to opioid dependence. This paper will briefly review findings from these studies and end with comments on the potential role of extended release naltrexone as a meaningful addition to current pharmacotherapies for treating opiod dependence and reducing HIV risk.
- 27 February 2016
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 11 (3) , 401-407
Antagonist Models for Relapse Prevention and Reducing HIV Risk
Naltrexone is an antagonist that binds tightly to mu-opioid receptors and blocks the subjective and analgesic effects of opioids. It does not produce physiologic dependence and precipitates withdrawal if administered to an opioid dependent person, thus starting it must begin with detoxification. It was first available in the mid-1970s as a 50 mg tablet that blocked opioids for 24-36 h if taken daily, or every 2-3 days at higher doses - for example: 100 mg Monday and Wednesday, 150 mg on Friday. From a pharmacological perspective it worked very well and was hoped to be an effective treatment but results were disappointing due to low patient interest and high dropout followed by relapse. Interest in it waned but rose again in the late 1990's when injecting opioid use and the rapid spread of HIV in the Russian Federation converged with an international interest in reducing the spread of HIV. One result was a series of meetings sponsored by the U.S. National Institute on Drug Abuse (NIDA) and Pavlov State Medical University in St. Petersburg, Russian Federation, on ways to reduce the spread of HIV in that country. Addiction treatment was a clear priority and discussions showed that naltrexone could have a role since agonist treatment is against Russian law but naltrexone is approved and the government funds over 25,000 beds for detoxification, which is the first step in starting naltrexone treatment. These meetings were followed by NIDA studies that showed better compliance to oral naltrexone than in prior U.S. studies with the expected reductions in HIV injecting risk for those that stayed in treatment. These events and findings provided a background and identified an infrastructure for the study that led to FDA approval of extended release injectable naltrexone for preventing relapse to opioid dependence. This paper will briefly review findings from these studies and end with comments on the potential role of extended release naltrexone as a meaningful addition to current pharmacotherapies for treating opiod dependence and reducing HIV risk.
- Top Cited Papers
Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial
Aims: To compare long‐term outcomes among participants randomized to buprenorphine or methadone.Design, Setting and Participants: Follow‐up was conducted in 2011–14 of 1080 opioid‐dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open‐label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in‐person interviews (~74% follow‐up interview rate) covering on average 4.5 years.Measurements: Outcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences.Findings: Mortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow‐up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P < 0.01, effect size (h) = 0.23 (0.09, 0.38); 5.8 days versus 4.4 days of past 30‐day heroin use, P < 0.05, effect size (d) = 0.14 (0.00, 0.28)]. Opioid use during the follow‐up period by randomization condition was also significant (F(7,39 600) = 3.16; P < 0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine.Conclusions: There are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.
Top Cited PapersLong‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial
Aims: To compare long‐term outcomes among participants randomized to buprenorphine or methadone.Design, Setting and Participants: Follow‐up was conducted in 2011–14 of 1080 opioid‐dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open‐label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in‐person interviews (~74% follow‐up interview rate) covering on average 4.5 years.Measurements: Outcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences.Findings: Mortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow‐up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P < 0.01, effect size (h) = 0.23 (0.09, 0.38); 5.8 days versus 4.4 days of past 30‐day heroin use, P < 0.05, effect size (d) = 0.14 (0.00, 0.28)]. Opioid use during the follow‐up period by randomization condition was also significant (F(7,39 600) = 3.16; P < 0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine.Conclusions: There are few differences in long‐term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.
- 16 March 2015
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 50 (8-9) , 1020-1023
You Can't Be in Recovery If You Are on Medication: A Concept Worth Retiring
It is probably best to start this paper by pointing to possible biases from using ideas generated by clinical anecdotes and ideas from someone that began his career studying psychoanalysis but spen...
- 16 March 2015
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 50 (8-9) , 1020-1023
You Can't Be in Recovery If You Are on Medication: A Concept Worth Retiring
It is probably best to start this paper by pointing to possible biases from using ideas generated by clinical anecdotes and ideas from someone that began his career studying psychoanalysis but spen...
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e66
Nurses’ screening and referral behaviors and opinions about brief interventions before and after implementation of Project Engage
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e66
Nurses’ screening and referral behaviors and opinions about brief interventions before and after implementation of Project Engage
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e165
Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting sustained-release naltrexone implant
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e165
Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting sustained-release naltrexone implant
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e245-e246
Association between age, substance use and health service use in Medicare elderly prostate cancer patients
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e245-e246
Association between age, substance use and health service use in Medicare elderly prostate cancer patients
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e224
Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e224
Implantable and oral naltrexone for preventing relapse in opiate addicts: A psychometric evaluation